Total and phosphorylated tau protein as biological markers of Alzheimer's disease.
Shaw, Leslie M
Hoessler, Yvonne C
Trojanowski, John Q
AffiliationDiscipline of Psychiatry, School of Medicine & Trinity College Institute of, Neuroscience, Laboratory of Neuroimaging & Biomarker Research, Trinity College,, University of Dublin, The Adelaide and Meath Hospital Incorporating The National , Children's Hospital, Tallaght, Dublin, Ireland. firstname.lastname@example.org
Biological Markers/blood/*cerebrospinal fluid
Predictive Value of Tests
MetadataShow full item record
CitationExp Gerontol. 2010 Jan;45(1):30-40. Epub 2009 Oct 22.
AbstractAdvances in our understanding of tau-mediated neurodegeneration in Alzheimer's disease (AD) are moving this disease pathway to center stage for the development of biomarkers and disease modifying drug discovery efforts. Immunoassays were developed detecting total (t-tau) and tau phosphorylated at specific epitopes (p-tauX) in cerebrospinal fluid (CSF), methods to analyse tau in blood are at the experimental beginning. Clinical research consistently demonstrated CSF t- and p-tau increased in AD compared to controls. Measuring these tau species proved informative for classifying AD from relevant differential diagnoses. Tau phosphorylated at threonine 231 (p-tau231) differentiated between AD and frontotemporal dementia, tau phosphorylated at serine 181 (p-tau181) enhanced classification between AD and dementia with Lewy bodies. T- and p-tau are considered "core" AD biomarkers that have been successfully validated by controlled large-scale multi-center studies. Tau biomarkers are implemented in clinical trials to reflect biological activity, mechanisms of action of compounds, support enrichment of target populations, provide endpoints for proof-of-concept and confirmatory trials on disease modification. World-wide quality control initiatives are underway to set required methodological and protocol standards. Discussions with regulatory authorities gain momentum defining the role of tau biomarkers for trial designs and how they may be further qualified for surrogate marker status.
- Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
- Authors: Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K
- Issue date: 2004 Jan
- Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
- Authors: Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Möller HJ
- Issue date: 2004 Mar
- Evaluation of cerebrospinal fluid phosphorylated tau<sub>231</sub> as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia.
- Authors: Kiđemet-Piskač S, Babić Leko M, Blažeković A, Langer Horvat L, Klepac N, Sonicki Z, Kolenc D, Hof PR, Boban M, Mimica N, Borovečki F, Šimić G
- Issue date: 2018 Aug
- Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia.
- Authors: Hampel H, Teipel SJ
- Issue date: 2004
- Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
- Authors: Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S
- Issue date: 2011 Feb